Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。

サイズ 価格(税別) 在庫  
JPY 30710.00 あり
JPY 18260.00 あり
JPY 28220.00 あり
JPY 61420.00 あり
JPY 161020.00 あり

カスタマーフィードバック(4)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy1xsDPxE1? MWC0POKhcA>? MV;icI9kc3NiMketU2hENWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDhdoFjdGVidH:geIhifCCxZjDiZZNidCCuZY\lcJM> MVOyOlM2ODV4NR?=
NP69 NYSyPGl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LaW2lEPTB;M{GuOlnDuTJwNUSg{txO NVGzcnpjOjZ{NUK1O|U>
NP460 NHrvenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjHSoxKSzVyPUKyMlg2yrFzLkG4JO69VQ>? M1vy[FI3OjV{NUe1
C666-1 NHfTRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjNNIhXUUN3ME2xPU46PcLzOD65N{DPxE1? MnjLNlYzPTJ3N{W=
C666-1 M2q5cWNmdGxiVnnhZoltcXS7IFHzd4F6 NXLlOGZkOTBiwsXN Mlf0OFghcA>? Mmr3SG1UVw>? M2nXeJNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIHPpd5Bt[XSrbh?= M2jYWlI3OjV{NUe1
C666-1  M1nU[2Z2dmO2aX;uJGF{e2G7 MoruNVAhyrWP M3PVXlI1KGh? NHTLXmVFVVOR NXrtXpJK[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ NV\zO4FwOjZ{NUK1O|U>
C666-1 NVfTbphtSXCxcITvd4l{KEG|c3H5 M3ntelExKML3TR?= NYnyXY46PDhxN{KgbC=> M4jNS2ROW09? MYPz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= MXeyOlI2OjV5NR?=
A549 M13ZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfQVpozPCCq NVnQNGhZUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= M4TLNFI3OTJ3MkOw
A549-NTC NXG0OoFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDnNlQhcA>? NVPUbYlQUUN3ME2xPU41OiEEsTCxMlk3KM7:TR?= NF3kOWkzPjF{NUKzNC=>
A549-920 MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqyOEBp MmHDTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? MmnWNlYyOjV{M{C=
CRL-5908 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnqe4UzPCCq MnK3TWM2OD1|OD63NUDDuSB{LkSzJO69VQ>? NYTwdHNGOjZzMkWyN|A>
L6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3PXJkyOMLizszNxsA> MX[yOE81QC95MjDo NF\zWmJFVVOR M1zyTolvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? M13KT|I2QDdzN{m0
C2C12 NE\lNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNOKh|ryPwrC= NF;QUGczPC92OD:3NkBp M37oPWROW09? NXuwWoFOcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w Mk\SNlU5PzF5OUS=
MCF-7  MVXGeY5kfGmxbjDBd5NigQ>? NYq1[VB{OTEEoN88US=> MoruSG1UVw>? MWrpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> NG\iNpIzPTdyMkewNy=>
DU4475  NIi1dVhHfW6ldHnvckBCe3OjeR?= NYHzSGNiPS9zMD:yNEDPxE1? NVLYS4tQOjUEoHi= NIPuSXBld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 NEnTfXgzPTV2N{G3OC=>
SMMC-7721 M3XLUGZ2dmO2aX;uJGF{e2G7 M4Xwb|ExKM7:TR?= MoDuOFghcA>? NHTTS3ZFVVOR MX7jZZV{\XNiRF7BJGRUSiCmYX3h[4U> M2fOWlI2PTR2M{[x
SMMC-7721 M4\KcmZ2dmO2aX;uJGF{e2G7 MmfSNVAh|ryP NEjwT5A1QCCq M{LDO2ROW09? MVPpcoR2[2W|IITo[UBkcHKxbXH0bY4u[m:3bnSgdJJwfGWrbjDJSmkyPiC2bzDwZZJ1cWGubImgcI9k[WyrenWgbY4hfGinIHP5eI9xdGG|bdMg NWHBW24{OjV3NESzOlE>
SMMC-7721 M1XUW2Z2dmO2aX;uJGF{e2G7 NX\hSGFJOTBizszN MVO0PEBp M{i5cGROW09? MWDpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7B MofBNlU2PDR|NkG=
SMMC-7721 M1f5fmZ2dmO2aX;uJGF{e2G7 NIfLNnYyOCEQvF2= NHvoV5Q{PiCq MkjLSG1UVw>? M{j3OINifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 M{nPRlI2PTR2M{[x
MCF-7 NXPwdZR5TnWwY4Tpc44hSXO|YYm= NVLjNGNZOTEEoN88US=> Ml\2NE0zPCCq M3X1Zolv\HWlZYOgdFU{KGGwZDDwNlEwS2myMR?= MWGyOVQ5OjN5Mx?=
OVCAR10 NUTrUHJCTnWwY4Tpc44hSXO|YYm= NEjscoMyOMLizszN Mki0NlFpyqB? MmPuSG1UVw>? NX;rcHhncW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NX;BbpBlOjV2Mk[1OFg>
NCI-H23 Ml\tSpVv[3Srb36gRZN{[Xl? MmXtNVDDqM7:TR?= NE\uWm8zOWkEoB?= M3PqUWROW09? MX3pcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MknKNlU1OjZ3NEi=
A2780 MlLZSpVv[3Srb36gRZN{[Xl? NX3vd4J{OTEEoN88US=> M4fyPFIycMLi MUXEUXNQ NFu5PW1qdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ M{fjWVI2PDJ4NUS4
NCI-H23 MlnRSpVv[3Srb36gRZN{[Xl? MVmxNOKh|ryP NXXWdId3OjGqwrC= NY\a[5UzTE2VTx?= NWPFbFVx\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> MWGyOVQzPjV2OB?=
A2780 MWLGeY5kfGmxbjDBd5NigQ>? M324TlExyqEQvF2= Mn3kNlFpyqB? NFLsN5dFVVOR NUDO[3hz\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> NF\TeGwzPTR{NkW0PC=>
HCT116  MoLLSpVv[3Srb36gRZN{[Xl? NEnvfXUyOCEEtV2= Ml\ONlQhcA>? NIPWPHZk[XW|ZYOgZUBxPTNvZHXw[Y5l\W62IITleJJieGyxaXSgS|Eu[XK{ZYP0JIlvKGSrcHzvbYQhUEOWMUG2JINtd26nczDEN{BidmRiREi= MmXHNlU{QDByNUW=
MCF-10CA1a NETwW5BHfW6ldHnvckBCe3OjeR?= MnnoNVDDqM7:TR?= NF;TOVc1QCCq M4LuSmROW09? M2PjZolvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? NUTxZmNVOjV{NUe3Nlk>
MCF-10A1  NWrRSW1oTnWwY4Tpc44hSXO|YYm= NEjEbnMyOMLizszN MVeyOE81QCCq MnvuSG1UVw>? NELjZ2xqdmirYnn0d{BucWe{YYTpc44hd2Zibn;ycYFtKGK{ZXHzeEBmeGm2aHXsbYFtyqB? NGjiXYczPTJ3N{eyPS=>
MCF-10CA1a NIPod4RHfW6ldHnvckBCe3OjeR?= NX30T5FzOTEEoN88US=> MUCyOEBp NIm3dZNFVVOR M2LjSYRm[3KnYYPld{B1cGViVFfGMe6zOy2rbnT1Z4VlKG2UTlGgcIV3\Wy|IH;mUW1ROi{EoF3NVFktKGGwZNMgbY51\We{aX9CpO6zyqB| MX6yOVI2Pzd{OR?=
MCF-10CA1a NFznTW1HfW6ldHnvckBCe3OjeR?= NIPaeJMyOMLizszN Mmf5NlQhcA>? NHv5do5FVVOR NWrHR4pEcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u M{XDdlI2OjV5N{K5
SK-BR-7 MUnGeY5kfGmxbjDBd5NigQ>? NW\0PY1UOTEEoN88US=> MVGyOEBp MkK0SG1UVw>? NIjNUZBqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NIO5c4EzPTJ3N{eyPS=>
SUM102PT NUm5VnhWTnWwY4Tpc44hSXO|YYm= MkLvNVDDqM7:TR?= MkXONlQhcA>? NF;IVnZFVVOR MUfpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NUTqcY9POjV{NUe3Nlk>
RAW 264.7 NHr6U5JHfW6ldHnvckBCe3OjeR?= NEDYNJQyOMLizszN M{XlZlMxKG2rbh?= NWXPXFFIeHKndnXueJMhfGinIIC1N{Bz\WS3Y4Tpc44hcW5icnXzdI9ve2VidH:gUHBU MV2yOVE4OjV2Nx?=
RAW 264.7 MYHGeY5kfGmxbjDBd5NigQ>? Ml7UNVDDqM7:TR?= NW\6dVBsOzBibXnu Mm\OdoVlfWOnczD0bIUhVFCVLXH1[41mdnSnZDD0bIUhVkZvzsrCJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhZ5Rqfmm2eR?= M3S4NFI2OTd{NUS3
RAW 264.7 NGfCOYJHfW6ldHnvckBCe3OjeR?= M2nyXlExyqEQvF2= NGXtXpY{OCCvaX6= M1vtOolvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=> MYGyOVE4OjV2Nx?=
MCF7  Mo\qR4VtdCCYaXHibYxqfHliQYPzZZk> M4\vSFIvPSEEtV2= M3TXblUh\A>? MkfISG1UVw>? NVPYV5RPe2Wwc3n0bZpmeyCPQ1[3JJRwKFCDUmCgbY5pcWKrdHnvci=> MnW1NlUxQDV7MEK=
MCF7  NFnRcWlHfW6ldHnvckBCe3OjeR?= MlzLNk42KML3TR?= NWHXfZloPDhiaB?= NFfVR21FVVOR M4n1bYRm[3KnYYPld{B1cGViaH;tc4xw\2:3czDEV2IhemWyYXnyJIZz\XG3ZX7jbYV{ M1L1ZlI2ODh3OUCy
ACHN M3jaeWNmdGxiVnnhZoltcXS7IFHzd4F6 Mn7RNE42NTFyIN88US=> M2LvWlAuPiCm Mle4SG1UVw>? MoDTbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUiyOVA3Pzd6Nx?=
Caki-2 NYLkVmxSS2WubDDWbYFjcWyrdImgRZN{[Xl? M{PmcVAvPS1zMDFOwG0> M2nOTFAuPiCm M1XU[2ROW09? MonjbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVnQcFluOjVyNke3PFc>
A498 NVrqcoV5S2WubDDWbYFjcWyrdImgRZN{[Xl? MXSwMlUuOTBizszN MmOzNE03KGR? MVPEUXNQ NF;GcG5qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2fvOlI2ODZ5N{i3
115 NHTDeoRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVuwMlUuOTBizszN NWW1NZBMOC14IHS= NUHiSVJTTE2VTx?= NVXadHVHcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoHSNlUxPjd5OEe=
117 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoewNE42NTFyIN88US=> MWGwMVYh\A>? NVTQ[XJNTE2VTx?= NFfwdJNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MlXUNlUxPjd5OEe=
ACHN NHXp[5ZHfW6ldHnvckBCe3OjeR?= M3znPFAvPS9zL{Wg{txO MoPCOFghcA>? NX7n[29TTE2VTx?= NYjOU5J5dGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= MnnkNlUxPjd5OEe=
Caki-2 Mm\kSpVv[3Srb36gRZN{[Xl? MnzpNE42NzFxNTFOwG0> M4PTXlQ5KGh? M3zpfmROW09? MYns[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NWHBdYhROjVyNke3PFc>
A498 MoO3SpVv[3Srb36gRZN{[Xl? NILUO3kxNjVxMT:1JO69VQ>? M1rke|Q5KGh? M4rVc2ROW09? NUftZ5FCdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= M4\tcVI2ODZ5N{i3
115 Mo\2SpVv[3Srb36gRZN{[Xl? NVPEOZVlOC53L{GvOUDPxE1? MoK5OFghcA>? Mn;QSG1UVw>? NHL1UHRt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MWSyOVA3Pzd6Nx?=
ACHN MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fUO|Uh|ryP NEfpT5c1QCCq M1\NXGROW09? MXvpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= M2DzNVI2ODZ5N{i3
Caki-2 NWLodYhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3UZ2JlPSEQvF2= MnTHOFghcA>? NFrUUmVFVVOR M3\lcYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> M3TUVlI2ODZ5N{i3
A498 NWTDUW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz4OUDPxE1? M3iwVVQ5KGh? NXHwcmZ1TE2VTx?= MkjObY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MX:yOVA3Pzd6Nx?=
115 M2nOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLDcFlCPSEQvF2= MU[0PEBp NHW0[3pFVVOR NX63dVlncW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MUWyOVA3Pzd6Nx?=
ACHN NF;IXZdHfW6ldHnvckBCe3OjeR?= Ml7POUDPxE1? NF7mVlk1QCCq NWW5c|lwTE2VTx?= M1jv[Ylv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M3LZd|I2ODZ5N{i3
Caki-2 MXjGeY5kfGmxbjDBd5NigQ>? M4rLUlUh|ryP MX:0PEBp MmS1SG1UVw>? MY\pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NXT3SYJTOjVyNke3PFc>
A498 M1[wWmZ2dmO2aX;uJGF{e2G7 M{TXNlUh|ryP NWTCTIk6PDhiaB?= MoXsSG1UVw>? NEm5Z|FqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg M{LGelI2ODZ5N{i3
115 MkO3SpVv[3Srb36gRZN{[Xl? MonuOUDPxE1? NFHZZVI1QCCq NXWzV|hpTE2VTx?= NHPo[olqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg Mmf4NlUxPjd5OEe=
MOLM-13 M3S1V2Z2dmO2aX;uJGF{e2G7 NV7PRoV{PsLizszN NXXEZ4V1OC16IHi= MVvEUXNQ NX3Qco4xcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV| MWCyOFg5PTB6Mh?=
MOLM-13 Mm\uSpVv[3Srb36gRZN{[Xl? NV;1fWV5PsLizszN M{XEVFYhcA>? NHf6XppFVVOR NESwTJhmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi|cEmw NUKwTo0zOjR6OEWwPFI>
HepG2 M2HJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXyR3E4OiCq NF\Ee3lFVVOR M2DrcWlEPTB;M{WuPFYhyrFiMj65JO69VQ>? Mn7MNlQ5QDR6MEm=
HepG2/As MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHpO|IhcA>? M2Dzc2ROW09? NFjwRpdKSzVyPU[4MlE{KMLzIEmuOkDPxE1? MUCyOFg5PDhyOR?=
SMMC7721 NXrsTZdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYS3NkBp Mn\uSG1UVw>? M1LpZWlEPTB;M{GuNlghyrFiND6yJO69VQ>? MVSyOFg5PDhyOR?=
SMMC7721/Ac MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33TXlczKGh? NXnhW3NqTE2VTx?= NWrUZ5QxUUN3ME21OU4zOSEEsTC1MlA{KM7:TR?= MX6yOFg5PDhyOR?=
Huh-7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XXVVczKGh? MXfEUXNQ MlfzTWM2OD1|Mz65OkDDuSB|Lkmg{txO MWiyOFg5PDhyOR?=
Hep3B M2LjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW4Nmg4OiCq NUDWXnZHTE2VTx?= M37rV2lEPTB;MkCuNVghyrFiMT64OEDPxE1? MkPtNlQ5QDR6MEm=
HepG2 NWW0U2VsSXCxcITvd4l{KEG|c3H5 MYrpcoR2[2W|IHHwc5B1d3Orcx?= NV\XUmhtOjR6OES4NFk>
SMMC7721 MYLBdI9xfG:|aYOgRZN{[Xl? MYXpcoR2[2W|IHHwc5B1d3Orcx?= MXuyOFg5PDhyOR?=
Huh-7 MWXBdI9xfG:|aYOgRZN{[Xl? NVLtd25LcW6mdXPld{BieG:ydH;zbZM> NUC5OIF{OjR6OES4NFk>
Hep3B MUnBdI9xfG:|aYOgRZN{[Xl? MoO3bY5lfWOnczDhdI9xfG:|aYO= NEXM[HgzPDh6NEiwPS=>
U2OS  MVrGeY5kfGmxbjDBd5NigQ>? NYfFTJZZOjBizszN Ml73NlQhcA>? M4OzPYlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= NY\4e2pROjR6NkeyOVk>
AML2 M2CxVWFxd3C2b4Ppd{BCe3OjeR?= NGTKV|czNzFyIN88US=> MUiyOE81QCCq MUDpcoR2[2W|IHHwc5B1d3Orcx?= MoD4NlQ3PTl5NEm=
MOML13 NGfoUotCeG:ydH;zbZMhSXO|YYm= NU\QUHhMOi9zMDFOwG0> MVuyOE81QCCq MlizbY5lfWOnczDhdI9xfG:|aYO= MoKzNlQ3PTl5NEm=
AML2 M3fDSGZ2dmO2aX;uJGF{e2G7 MmLKNVDPxE1? MW[yM|QhcA>? MV;pcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= M2Gyd|I1PjV7N{S5
AML3 MV7GeY5kfGmxbjDBd5NigQ>? MlL5NVDPxE1? MYKyM|QhcA>? NVvKcFgxcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NGPRS3kzPDZ3OUe0PS=>
MOML13 NES3OFdHfW6ldHnvckBCe3OjeR?= NV7XWnVQOTEQvF2= MYmyM|QhcA>? NHLXV4tqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NI\PXJQzPDZ3OUe0PS=>
BeWo M3\OcmZ2dmO2aX;uJGF{e2G7 NF[zfpg{OCEEtV2= NEnufJIzPCCq NHX1TlBqdmO{ZXHz[ZMheDV|LDDN[I0zNCCyMkGgZY5lKFC3bXGgZZQhfGinIIDyc5RmcW5ibHX2[Yw> NUPsVYkxOjR2OUixOVQ>
BeWo M1zDZWFxd3C2b4Ppd{BCe3OjeR?= NGHndm8{OCEEtV2= MoHONlQhcA>? MUnpcoNz\WG|ZYOgZZBweHSxc3nz MYOyOFQ6QDF3NB?=
OCI M1XHPWZ2dmO2aX;uJGF{e2G7 M1WwbVExKM7:TR?= MUmyOEBp MkLEeZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w MnnjNlQ1PzN3NkK=
MOLM NHvRUmtHfW6ldHnvckBCe3OjeR?= NICyd5EyOCEQvF2= M4SweFI1KGh? M4HhU5VxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= NU[yeJpxOjR2N{O1OlI>
U2OS  NETPUItHfW6ldHnvckBCe3OjeR?= NILmR2UzOCEQvF2= MYiyOEBp M2mxVIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? MX2yOFM3PjByNx?=
RKO NYDUT2xrTnWwY4Tpc44hSXO|YYm= NHXxWpEzOCEQvF2= MUOyOEBp NWf3OVN[cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= MmrTNlQ{PjZyMEe=
U2OS  MofTSpVv[3Srb36gRZN{[Xl? NUP2ZZBbOjBizszN MonMNlQhcA>? MYLpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= M4\Vd|I1OzZ4MEC3
RKO NHPhepZHfW6ldHnvckBCe3OjeR?= Ml3PNlAh|ryP NHzxbI8zPCCq M3iy[Ilv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u NX3lcVdyOjR|Nk[wNFc>
SMMC-7721  NEKydmZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2nJUlEvOjVvMkCg{txO MYqyOE81QC95MjDo NIDDOFdFVVOR M1XZVolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NGfDVG4zPDJ6NkOxNi=>
HuH-7 NEGzfItE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEji[XAyNjJ3LUKwJO69VQ>? NH\0SmMzPC92OD:3NkBp M2fS[WROW09? NITMN2hqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MoTpNlQzQDZ|MUK=
SMMC-7721  MWXBdI9xfG:|aYOgRZN{[Xl? MkjZNlAh|ryP MYK0PEBp NX;B[YJvTE2VTx?= M2j4Uolv\HWlZYOgZZBweHSxc3nz NEnKWHEzPDJ6NkOxNi=>
HuH-7 MVXBdI9xfG:|aYOgRZN{[Xl? MVOyNEDPxE1? NVvOfVlRPDhiaB?= MVHEUXNQ MXPpcoR2[2W|IHHwc5B1d3Orcx?= NHTCcXozPDJ6NkOxNi=>
SMMC-7721  M37PbmZ2dmO2aX;uJGF{e2G7 MXKxNEDPxE1? M2HNSFM3KGh? M3jZfGROW09? M4G3doRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ M2DKPVI1Ojh4M{Gy
HuH-7 NWKwTVVkTnWwY4Tpc44hSXO|YYm= NVfxR5pnOTBizszN MlLyN|YhcA>? MYnEUXNQ Ml;J[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MYmyOFI5PjNzMh?=
AT2 NG\mbZpHfW6ldHnvckBCe3OjeR?= NX;oVIpsPS9zMDFOwG0> NG\4b2ht\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NHqwbo8zPDJ2MEKwNy=>
REH M1PpfWZ2dmO2aX;uJGF{e2G7 MoPPOU8yOCEQvF2= NEO3[25t\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= M{fuS|I1OjRyMkCz
UoCB6 MlfwSpVv[3Srb36gRZN{[Xl? M1TsOlUwOTBizszN NIj0PVRt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= MXOyOFI1ODJyMx?=
AT2 M332eGNmdGxiVnnhZoltcXS7IFHzd4F6 M2LkWFAuOjVizszN MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NYn2c4hMOjR{NECyNFM>
REH M3Po[2NmdGxiVnnhZoltcXS7IFHzd4F6 NXftRpBwOC1{NTFOwG0> MVLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M2W4[|I1OjRyMkCz
UoCB6 M3nFOWNmdGxiVnnhZoltcXS7IFHzd4F6 MXSwMVI2KM7:TR?= NH;rZYxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M3\4dVI1OjRyMkCz
A2780 M4eySWZ2dmO2aX;uJGF{e2G7 NVrrNlB[PS9zMD:yNEDPxE1? NEHrboIzPCCq MWn1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? NFi3RmYzPDF|NkG0Oy=>
H460 MXLGeY5kfGmxbjDBd5NigQ>? NHroOHA2NzFyL{KwJO69VQ>? M1j3T|I1KGh? MUf1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? M4XxU|I1OTN4MUS3
Lovo  NVzmTWczTnWwY4Tpc44hSXO|YYm= NUDLWXBUPS9zMD:yNEDPxE1? NIPv[44zPCCq NXzO[mFVfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= M3\pN|I1OTN4MUS3
A2780 MnPJRZBweHSxc3nzJGF{e2G7 NI\G[HY2NzFyL{KwJO69VQ>? MXSyOEBp M1n0VIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NGHQWZkzPDF|NkG0Oy=>
H460 NIOyVW1CeG:ydH;zbZMhSXO|YYm= MlzsOU8yOC9{MDFOwG0> NF[wRXMzPCCq NYnyUIJR\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NF7DWXYzPDF|NkG0Oy=>
Lovo  MmTwRZBweHSxc3nzJGF{e2G7 NFO3TYM2NzFyL{KwJO69VQ>? MmjGNlQhcA>? M3fHfYVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MWiyOFE{PjF2Nx?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2信号経路図

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID